Følg os på
Principal/ Senior Analytical Development Scientist

Embark on the forefront of developing a vaccine with MinervaX, where an exciting position awaits you in an international company.

 

As Principal/ Senior Analytical Development Scientist at MinervaX, you will play a central role in developing analytical methods for MinervaX’s prophylactic vaccine targeting Group B Streptococcus (GBS).

 Your main responsibilities include:

  • Manage the development, pre-validation, and validation of analytical methods to support vaccine projects.
  • Life cycle management of excising analytical methods
  • Take ownership of the stability program
  • Overseeing trending and preparing comprehensive stability reports.

Your qualifications include at least three years of experience in the pharmaceutical and/or biotechnology industry, where you have been actively working with analytical development initiatives, requiring expertise in analytical development, validation of methods, collaboration with external partners, and proficiency in ICH stability relevant to biopharmaceuticals.

You are a motivated person that is adaptable and at ease in a dynamic, collaborative, and innovative setting, You excel in balancing strategic responsibilities while remaining hands-on as required. With an energetic and passionate demeanor, you bring ambition to contribute meaningfully within a vibrant biotech organization.

MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. MinervaX is developing a GBS vaccine for maternal immunization, likely to have superior characteristics compared with other GBS vaccine candidates in development. The latter are based on traditional capsular polysaccharide (CPS) conjugate technology. By contrast, MinervaX’s vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family). Given the broad distribution of proteins contained in the vaccine on GBS strains globally, it is expected that MinervaX’s vaccine will confer protection against virtually 100% of all GBS isolates.

Domicile: Commuting distance from the MinervaX office in Copenhagen.

For more details about the job or the company, please CEO Jørn Duhn, Unique Human Capital, on M: +45 21 75 19 25, jd@uhc.dk. All applications must be in English and are treated confidentially.

Unique Human Capital A/S
/ /
cvr: 31502705
Jægersborg Alle 4
2920 Charlottenlund
Skelagervej 375E
9000 Aalborg
Christiansgade 30
8000 Aarhus C
We are more than 200 people who work with knowledge, creativity and technology
Strategic counselling Marketing & Advertisement UX & Digital development PR & Communication Recruitment of leaders and specialists Event design

Privacy Statement Business Ethics Cookie Policy